197 related articles for article (PubMed ID: 19276267)
1. Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases.
Chavin G; Sheinin Y; Crispen PL; Boorjian SA; Roth TJ; Rangel L; Blute ML; Sebo TJ; Tindall DJ; Kwon ED; Karnes RJ
Clin Cancer Res; 2009 Mar; 15(6):2174-80. PubMed ID: 19276267
[TBL] [Abstract][Full Text] [Related]
2. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome.
Zang X; Thompson RH; Al-Ahmadie HA; Serio AM; Reuter VE; Eastham JA; Scardino PT; Sharma P; Allison JP
Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19458-63. PubMed ID: 18042703
[TBL] [Abstract][Full Text] [Related]
3. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy.
Roth TJ; Sheinin Y; Lohse CM; Kuntz SM; Frigola X; Inman BA; Krambeck AE; McKenney ME; Karnes RJ; Blute ML; Cheville JC; Sebo TJ; Kwon ED
Cancer Res; 2007 Aug; 67(16):7893-900. PubMed ID: 17686830
[TBL] [Abstract][Full Text] [Related]
4. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
[TBL] [Abstract][Full Text] [Related]
5. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy.
July LV; Akbari M; Zellweger T; Jones EC; Goldenberg SL; Gleave ME
Prostate; 2002 Feb; 50(3):179-88. PubMed ID: 11813210
[TBL] [Abstract][Full Text] [Related]
6. T-cell co-regulatory molecule expression in renal angiomyolipoma and pulmonary lymphangioleiomyomatosis.
Boorjian SA; Sheinin Y; Crispen PL; Lohse CM; Leibovich BC; Kwon ED
Urology; 2009 Dec; 74(6):1359-64. PubMed ID: 19501877
[TBL] [Abstract][Full Text] [Related]
7. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.
Tosco L; Laenen A; Briganti A; Gontero P; Karnes RJ; Albersen M; Bastian PJ; Chlosta P; Claessens F; Chun FK; Everaerts W; Gratzke C; Graefen M; Kneitz B; Marchioro G; Salas RS; Tombal B; Van den Broeck T; Moris L; Battaglia A; van der Poel H; Walz J; Bossi A; De Meerleer G; Haustermans K; Van Poppel H; Spahn M; Joniau S
Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):407-412. PubMed ID: 28485390
[TBL] [Abstract][Full Text] [Related]
8. Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence.
Miyata Y; Sakai H; Kanda S; Igawa T; Hayashi T; Kanetake H
Urology; 2004 Jun; 63(6):1184-90. PubMed ID: 15183987
[TBL] [Abstract][Full Text] [Related]
9. Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer.
Mendes AA; Lu J; Kaur HB; Zheng SL; Xu J; Hicks J; Weiner AB; Schaeffer EM; Ross AE; Balk SP; Taplin ME; Lack NA; Tekoglu E; Maynard JP; De Marzo AM; Antonarakis ES; Sfanos KS; Joshu CE; Shenderov E; Lotan TL
Cancer; 2022 Jun; 128(12):2269-2280. PubMed ID: 35333400
[TBL] [Abstract][Full Text] [Related]
10. Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.
Chang SS; Reuter VE; Heston WD; Hutchinson B; Grauer LS; Gaudin PB
Cancer; 2000 Jan; 88(2):407-15. PubMed ID: 10640975
[TBL] [Abstract][Full Text] [Related]
11. B7-H3 over expression in prostate cancer promotes tumor cell progression.
Yuan H; Wei X; Zhang G; Li C; Zhang X; Hou J
J Urol; 2011 Sep; 186(3):1093-9. PubMed ID: 21784485
[TBL] [Abstract][Full Text] [Related]
12. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival.
Boorjian SA; Sheinin Y; Crispen PL; Farmer SA; Lohse CM; Kuntz SM; Leibovich BC; Kwon ED; Frank I
Clin Cancer Res; 2008 Aug; 14(15):4800-8. PubMed ID: 18676751
[TBL] [Abstract][Full Text] [Related]
13. The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
Miyake H; Sakai I; Inoue TA; Hara I; Fujisawa M
Urol Int; 2006; 77(2):122-6. PubMed ID: 16888415
[TBL] [Abstract][Full Text] [Related]
14. Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population?
Liu Y; Vlatkovic L; Sæter T; Servoll E; Waaler G; Nesland JM; Giercksky KE; Axcrona K
Int J Urol; 2012 Aug; 19(8):749-56. PubMed ID: 22487487
[TBL] [Abstract][Full Text] [Related]
15. Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy.
Stewart SB; Cheville JC; Sebo TJ; Frank I; Boorjian SA; Thompson RH; Gettman MT; Tollefson MK; Umbriet EC; Psutka SP; Bergstralh EJ; Rangel L; Karnes RJ
Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):332-7. PubMed ID: 25156060
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical Analysis of Radical Prostatectomy Specimens After 8 Months of Neoadjuvant Hormonal Therapy.
Paterson RF; Gleave ME; Jones EC; Zubovits JT; Goldenberg SL; Sullivan LD
Mol Urol; 1999; 3(3):277-286. PubMed ID: 10851334
[TBL] [Abstract][Full Text] [Related]
17. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis.
Benzon B; Zhao SG; Haffner MC; Takhar M; Erho N; Yousefi K; Hurley P; Bishop JL; Tosoian J; Ghabili K; Alshalalfa M; Glavaris S; Simons BW; Tran P; Davicioni E; Karnes RJ; Boudadi K; Antonarakis ES; Schaeffer EM; Drake CG; Feng F; Ross AE
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):28-35. PubMed ID: 27801901
[TBL] [Abstract][Full Text] [Related]
18. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial.
Bullock MJ; Srigley JR; Klotz LH; Goldenberg SL
Am J Surg Pathol; 2002 Nov; 26(11):1400-13. PubMed ID: 12409716
[TBL] [Abstract][Full Text] [Related]
19. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation.
Matsushima H; Goto T; Hosaka Y; Kitamura T; Kawabe K
Cancer; 1999 Apr; 85(8):1822-7. PubMed ID: 10223578
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis.
Liu W; Yao Y; Liu X; Liu Y; Zhang GM
Asian J Androl; 2021; 23(4):429-436. PubMed ID: 33586699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
